Work

XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)

Year: 2023

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000203823

Authors: Jacqueline French, Roger Porter, Emilio Perucca, Martin Brodie, Michael Rogawski, Cynthia Harden, Jenny Qian, Constanza Luzon-Rosenblut, Christopher Kenney, Gregory Beatch

Institutions: NYU Langone Health, New York University, University of Pennsylvania, The University of Melbourne, Austin Health, Monash University, University of Glasgow, University of California, Davis, Xenon Pharmaceuticals (Canada)

Language: English

Topic: Epilepsy research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367303360

FWCI: 0.408

Cites:

Cited by: 2

Related to: 10